interior page header ver2

Tildren® (Rx)

(tiludronate disodium) 500mg

Tildren® is indicated for the control of clinical signs associated with navicular syndrome in horses.

Navicular syndrome is the most common cause of chronic forelimb lameness in performance horses. It is a degenerative process instigated by mechanical forces.


  • Restores balance to the process of bone remodeling
  • Decrease mineral loss and slow the rate of bone turnover
  • Alleviate pain induced by abnormal osteolysis

Tildren® Activity

Tildren® restores balance to the process of bone remodeling.

Tildren® partially inhibits bone resorption by:

  • Inhibiting osteoclastic activity (Destroys excess osteoclasts)
  • Not modifying osteoblastic activity (Bone formation remains the same)
  • Slowing the rate of bone turnover (Bone resorption is slowed, but not stopped)

Tildren® mode of action:


1 Inhibition of osteoclast pump

2 Disruption of the osteoclast cytoskeleton

3 Creation of a cytotoxin

Safety Recommendations


  • Tildren®-related clinical signs of colic are well characterized and self-limiting


  • Do not use NSAIDs concurrently with Tildren®
  • Concurrent use may increase the risk of renal toxicity and acute renal failure


  • Horses should be well hydrated prior to administration


  • Do not use in horses with known hypersensitivity to tiludronate disodium or to mannitol.
  • Do not use in horses with impaired renal function or with a history of renal disease.
  • Bisphosphonates are excreted by the kidney; therefore, conditions causing renal impairment may increase plasma bisphosphonate concentrations resulting in an increased risk for adverse reactions.


  • The safe use of Tildren® has not been evaluated in horses less than 4 years of age.
  • Bisphosphonates should not be used in pregnant or lactating mares, or mares intended for breeding.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Always consult with your veterinarian if you suspect your horse may have navicular syndrome as the clinical signs can vary.

Tildren® is a registered trademark of Ceva Santé Animale, S.A.

Available Pack Sizes

Product Code Unit Size Case
1TIL004 500mg 12

Podcast:  Navicular Syndrome Update

From initial diagnosis to hoof care and bisphosphonate use, find out the newest information about this debilitating condition.

Recorded at Ask TheHorse Live


Review recent studies of Tiludronate and Tildren.

Documents to Download

*Rx. Federal law restricts this product to use by or on the order of a licensed veterinarian

Use Medicines Responsibly.
See for information about our full range of products.

For complete product information, including contra-indications, see the datasheet.

Contact Us - US

Bimeda® US - Head Office
One Tower Lane, Suite 2250,
Oakbrook Terrace, IL 60181
Phone: 1 888 524 6332